BioNTech’s (BNTX) Buy Rating Reaffirmed at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report sent to investors on Monday morning,MarketScreener reports.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut their price objective on shares of BioNTech from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. TD Cowen lowered their target price on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. Raymond James Financial restated an “outperform” rating on shares of BioNTech in a research report on Tuesday, March 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Finally, BMO Capital Markets decreased their price objective on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $133.13.

BioNTech Stock Up 1.3%

BNTX stock opened at $96.70 on Monday. The stock has a market cap of $24.45 billion, a PE ratio of -18.45 and a beta of 1.58. The firm’s 50-day simple moving average is $98.57 and its 200 day simple moving average is $101.04. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%.The firm had revenue of $1.06 billion during the quarter. As a group, sell-side analysts predict that BioNTech will post -3.88 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its position in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. EFG International AG bought a new stake in shares of BioNTech in the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after acquiring an additional 260 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of BioNTech in the third quarter worth $36,000. Finally, Huntington National Bank increased its position in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.